Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting Cancer Neoantigens Through Multi-Epitope Vaccination for Tumour Prevention in Lynch Syndrome: a Phase I/II Clinical Trial.

NCT07412197 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT07412197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07412197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting Cancer Neoantigens Through Multi-Epitope Vaccination for Tumour Prevention in Lynch Syndrome: a Phase I/II Clinical Trial.
Lead sponsor
Radboud University Medical Center
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
June 30, 2036
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lynch syndrome